Key Dengue Vaccine Market Trend for 2025-2034: Advancements In Dengue Tetravalent Vaccines Enhance Comprehensive Protection Against All Serotypes

What Is the Future Outlook for the Dengue Vaccine Market's Size and Growth Rate?
In the past few years, the dengue vaccine market has experienced significant growth. From $0.64 billion in 2024, it is projected to reach $0.72 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%. This notable expansion during the historical period can be credited to factors such as an increase in travel and urbanization trends, a rising demand for efficient vaccines, increased levels of exposure to foreign travel, improvements in healthcare services, and the augmentation of mass vaccination campaigns.

Expectation exists for swift expansion in the dengue vaccine market in the coming years. By 2029, it's projected to reach $1.14 billion with a compound annual growth rate (CAGR) of 12.3%. This growth during the forecast period is attributed to a rise in dengue cases, various organizations' initiatives, heightened clinical trials and an increased focus on multi-strain and tetravalent vaccine formulations. The forecast period reveals trends of growing demand for preventative vaccines, breakthroughs in vaccine technology, development of combination vaccines, increase in research and clinical trials for novel vaccine candidates, and emphasis on enhancing vaccine efficacy and safety profiles.

What Is Stimulating Growth in the Dengue Vaccine Market?
The surge in cases of dengue fever is projected to boost the development of the dengue vaccine market in the future. Dengue fever, a contagious infection transmitted by Aedes aegypti mosquitoes, results in high fever, headaches, joint pain, and skin rashes. The escalation in cases is attributed to factors such as climate change, urbanization, ineffective mosquito control, and the evolution of the virus. The dengue vaccine stimulates the immune response to recognize and fight off the dengue virus, thereby mitigating the severity of the infection and lowering the potential for dire complications, leading to a reduction in the number of cases and resultant hospitalizations. For example, the World Health Organization, a Switzerland-based international body, reported that dengue cases in the American region exceeded 7 million in April 2024, up from 4.6 million cases in 2023. Thus, the escalating number of dengue fever cases is propelling the growth of the dengue vaccine market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

Which Key Market Leaders Are Driving Dengue Vaccine Industry Growth?
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

What Are the Emerging Trends in the Dengue Vaccine Industry?
Leading entities in the dengue vaccine sector are making strides in creating improved vaccine compositions, like the dengue tetravalent vaccine, to provide defense against all four kinds of dengue virus in one formula. This particular vaccine offers resistance to all four dengue virus variants (DEN-1, DEN-2, DEN-3, and DEN-4), providing a holistic shield against dengue fever. To illustrate, in December 2022, the Japan-based Takeda Pharmaceutical Company was granted European Commission (EC) authorization for the application of the QDENGA vaccine for people aged 4 and above. This is a live-attenuated vaccine which is utilized in many countries where dengue is endemic as a preventive measure against dengue fever. Using a weakened version of the dengue serotype two viruses as a genetic base for the remaining three serotypes, this vaccine is administered in two half-milliliter doses at 0 and 3 months and is designed for use in individuals from the age of four. A Phase 3 trial demonstrated that Qdenga's effectiveness reaches approximately 80.2% against dengue, demonstrating superior outcomes in terms of reducing hospital admissions. Its protective impact lasts about 4.5 years, outstripping the duration of numerous other vaccines.

What Are the Main Segments in the Dengue Vaccine Market?
The dengue vaccinemarket covered in this report is segmented -

1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users

Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report

Which Geographic Area Leads the Dengue Vaccine Market?
Asia-Pacific was the largest region in the dengue vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Dengue Vaccine Global Market Report?

- Market Size Analysis: Analyze the Dengue Vaccine Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Dengue Vaccine Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Dengue Vaccine Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Dengue Vaccine Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19026

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.